ARTICLE | Company News
MorphoSys and Biogen in genomics deal
January 2, 2001 8:00 AM UTC
MorphoSys (NMarkt:MOR) will use its HuCAL technology to generate antibodies against Expressed Sequence Tags (ESTs) to validate drug targets in BGEN's genomics programs. MOR will receive an upfront tec...